{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:28:45Z","timestamp":1786786125718,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07008-x","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:13:32Z","timestamp":1778930012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative and integrated application of flow cytometry and next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Jungao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqiang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"7008_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"7008_CR2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH (2023) Acute myeloid leukaemia. Lancet 401:2073\u20132086. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3","journal-title":"Lancet"},{"key":"7008_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev 36:70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005","journal-title":"Blood Rev"},{"key":"7008_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E et al (2021) Acute myeloid leukemia: current progress and future directions. Blood Cancer J 11:41. https:\/\/doi.org\/10.1038\/s41408-021-00425-3","journal-title":"Blood Cancer J"},{"key":"7008_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131:1275\u20131291. https:\/\/doi.org\/10.1182\/blood-2017-09-801498","journal-title":"Blood"},{"key":"7008_CR6","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138:2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"key":"7008_CR7","doi-asserted-by":"publisher","unstructured":"Chea M, Rigolot L, Canali A, Vergez F (2024) Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25042150","DOI":"10.3390\/ijms25042150"},{"key":"7008_CR8","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD et al (2020) Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. Jama Oncol 6:1890\u20131899. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4600","journal-title":"Jama Oncol"},{"key":"7008_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pathol.2022.11.003","volume":"55","author":"M Krigstein","year":"2023","unstructured":"Krigstein M, Iland HJ, Wei AH (2023) Applying molecular measurable residual disease testing in acute myeloid leukaemia. Pathology 55:1\u201307. https:\/\/doi.org\/10.1016\/j.pathol.2022.11.003","journal-title":"Pathology"},{"key":"7008_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/leu.2015.252","volume":"30","author":"W Zeijlemaker","year":"2016","unstructured":"Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, Snel AN, Veldhuizen D et al (2016) A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia 30:439\u2013446. https:\/\/doi.org\/10.1038\/leu.2015.252","journal-title":"Leukemia"},{"key":"7008_CR11","doi-asserted-by":"publisher","first-page":"e703","DOI":"10.1097\/HS9.0000000000000703","volume":"6","author":"C Notice","year":"2022","unstructured":"Notice C (2022) Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. Hemasphere 6:e703. https:\/\/doi.org\/10.1097\/HS9.0000000000000703","journal-title":"Hemasphere"},{"key":"7008_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/cyto.b.22140","volume":"104","author":"SA Wang","year":"2023","unstructured":"Wang SA, Jorgensen JL, Hu S, Jia F, Li S, Loghavi S et al (2023) Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal\/measurable residual disease detection. Cytometry B Clin Cytom 104:356\u2013366. https:\/\/doi.org\/10.1002\/cyto.b.22140","journal-title":"Cytometry B Clin Cytom"},{"key":"7008_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.2023.283520","volume":"109","author":"LW Dillon","year":"2024","unstructured":"Dillon LW, Higgins J, Nasif H, Othus M, Beppu L, Smith TH et al (2024) Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia. Haematologica 109:401\u2013410. https:\/\/doi.org\/10.3324\/haematol.2023.283520","journal-title":"Haematologica"},{"key":"7008_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-023-00833-7","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Solis-Ruiz J, Yang F, Long N, Tong CH, Lacbawan FL et al (2023) NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood Cancer J 13:59. https:\/\/doi.org\/10.1038\/s41408-023-00833-7","journal-title":"Blood Cancer J"},{"key":"7008_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jama.2015.9643","volume":"314","author":"JM Klco","year":"2015","unstructured":"Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S et al (2015) Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA 314:811\u2013822. https:\/\/doi.org\/10.1001\/jama.2015.9643","journal-title":"JAMA"},{"key":"7008_CR16","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","volume":"36","author":"K Morita","year":"2018","unstructured":"Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K et al (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788\u20131797. https:\/\/doi.org\/10.1200\/JCO.2017.77.6757","journal-title":"J Clin Oncol"},{"key":"7008_CR17","doi-asserted-by":"publisher","unstructured":"Baer MR, Stewart CC, Dodge RK, Leget G, Sule N, Mrozek K et al (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97: 3574-80. https:\/\/doi.org\/10.1182\/blood.v97.11.3574","DOI":"10.1182\/blood.v97.11.3574"},{"key":"7008_CR18","doi-asserted-by":"publisher","unstructured":"Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A (2013) rt al.From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. ;43(1110):11.10.1\u201311.10.33. https:\/\/doi.org\/10.1002\/0471250953.bi1110s43","DOI":"10.1002\/0471250953.bi1110s43"},{"issue":"36","key":"7008_CR19","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1073\/pnas.1208715109","volume":"109","author":"MW Schmitt","year":"2012","unstructured":"Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA (2012) Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A 109(36):14508\u201314513. https:\/\/doi.org\/10.1073\/pnas.1208715109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"7008_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","volume":"29","author":"G Marcucci","year":"2011","unstructured":"Marcucci G, Haferlach T, D\u00f6hner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29(5):475\u2013486. https:\/\/doi.org\/10.1200\/JCO.2010.30.2554","journal-title":"J Clin Oncol"},{"issue":"8","key":"7008_CR21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.cancergen.2011.06.003","volume":"204","author":"CC So","year":"2011","unstructured":"So CC, Wan TS, Chow JL, Hui KC, Choi WW, Lam CC (2011) A single-center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia\u2013evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients. Cancer Genet 204(8):430\u2013438. https:\/\/doi.org\/10.1016\/j.cancergen.2011.06.003","journal-title":"Cancer Genet"},{"issue":"2","key":"7008_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/leu.2014.242","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Othus M, Burnett AK, L\u00f6wenberg B, Kantarjian HM, Ossenkoppele GJ et al (2015) Resistance prediction in AML: analysis of 4601 patients from MRC\/NCRI, HOVON\/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 29(2):312\u2013320. https:\/\/doi.org\/10.1038\/leu.2014.242","journal-title":"Leukemia"},{"key":"7008_CR23","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/leu.2017.113","volume":"31","author":"CS Hourigan","year":"2017","unstructured":"Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB (2017) Measurable residual disease testing in acute myeloid leukaemia. Leukemia 31:1482\u20131490. https:\/\/doi.org\/10.1038\/leu.2017.113","journal-title":"Leukemia"},{"key":"7008_CR24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al HA, Zeilemaker A et al (2018) Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med 378:1189\u20131199. https:\/\/doi.org\/10.1056\/NEJMoa1716863","journal-title":"N Engl J Med"},{"key":"7008_CR25","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C et al (2018) Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132:1703\u20131713. https:\/\/doi.org\/10.1182\/blood-2018-02-829911","journal-title":"Blood"},{"key":"7008_CR26","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s41375-024-02275-x","volume":"38","author":"S Scott","year":"2024","unstructured":"Scott S, Devonshire A, Dillon R, Thiede C, Cross N, White HE et al (2024) Recommendations from the AML molecular MRD expert advisory board. Leukemia 38:1638\u20131641. https:\/\/doi.org\/10.1038\/s41375-024-02275-x","journal-title":"Leukemia"},{"key":"7008_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A et al (2016) Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med 374:422\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1507471","journal-title":"N Engl J Med"},{"key":"7008_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","volume":"35","author":"M Balsat","year":"2017","unstructured":"Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A et al (2017) Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol 35:185\u2013193. https:\/\/doi.org\/10.1200\/JCO.2016.67.1875","journal-title":"J Clin Oncol"},{"key":"7008_CR29","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","volume":"132","author":"T Kim","year":"2018","unstructured":"Kim T, Moon JH, Ahn JS, Kim YK, Lee SS, Ahn SY et al (2018) Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. Blood 132:1604\u20131613. https:\/\/doi.org\/10.1182\/blood-2018-04-848028","journal-title":"Blood"},{"key":"7008_CR30","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","volume":"33","author":"W Zeijlemaker","year":"2019","unstructured":"Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC et al (2019) CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia 33:1102\u20131112. https:\/\/doi.org\/10.1038\/s41375-018-0326-3","journal-title":"Leukemia"},{"key":"7008_CR31","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41409-019-0729-4","volume":"55","author":"M Othus","year":"2020","unstructured":"Othus M, Gale RP, Hourigan CS, Walter RB (2020) Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transpl 55:843\u2013850. https:\/\/doi.org\/10.1038\/s41409-019-0729-4","journal-title":"Bone Marrow Transpl"},{"key":"7008_CR32","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood.2019002959","volume":"135","author":"R Dillon","year":"2020","unstructured":"Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A et al (2020) Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood 135:680\u2013688. https:\/\/doi.org\/10.1182\/blood.2019002959","journal-title":"Blood"},{"key":"7008_CR33","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/leu.2011.97","volume":"25","author":"S Schnittger","year":"2011","unstructured":"Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T (2011) Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 25:1297\u20131304. https:\/\/doi.org\/10.1038\/leu.2011.97","journal-title":"Leukemia"},{"key":"7008_CR34","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","volume":"29","author":"J Kronke","year":"2011","unstructured":"Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI et al (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 29:2709\u20132716. https:\/\/doi.org\/10.1200\/JCO.2011.35.0371","journal-title":"J Clin Oncol"},{"key":"7008_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y et al (2016) Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? J Clin Oncol 34:329\u2013336. https:\/\/doi.org\/10.1200\/JCO.2015.63.3826","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07008-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07008-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07008-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:11Z","timestamp":1786785611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07008-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["7008"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07008-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving human participants were reviewed and approved by the Ganzhou People\u2019s Hospital Ethics Committee (Ganzhou, China; approval no. PJB2025-146-01). The requirement for informed consent was waived by the ethics committee due to the retrospective nature of the study and the use of fully anonymized clinical data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"324"}}